Skip to content

mAbXmise ITDM2

by Promise proteomics France EUDAMED

Ref ITDM2

EMDN W0102080701,W0102080702,W01020899

Regulatory status

as of 24 Oct 2026

RegionAuthorizationNumberDateStatus
European UnionCE/IVDR Number3770024131INF-TDM2V Basic UDI-DIDate24 Jan 2025RegisteredStatusActive

Coverage

1 jurisdiction

SwedenFinlandFinlandSwedenFinlandFinlandSwedenSwedenLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyGermanyPolandPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaPolandFranceFranceAustriaHungaryRomaniaFranceFranceSloveniaBulgariaPortugalSpainSpainItalySpainSpainCroatiaGreeceMaltaCyprus
  • Active
  • Not covered

European Union — CE/IVDR Active

Certificates: none listed in EUDAMED

Specification

EUDAMED · synced 23 Oct 2026

Device Name
mAbXmise – Monoclonal antibodies quantification Kit Multiplex Infliximab, Adalimumab, Obinutuzumab, Secukinumab, Tocilizumab, Ustekinumab, Vedolizumab
Model / Reference
ITDM2
Primary DI / UDI-DI
03770024131000
Basic UDI-DI
3770024131INF-TDM2V
Direct Marketing DI
03770024131000
EMDN Code
W0102080701,W0102080702,W01020899
Device Class
Class B
Market of Registration
France

Manufacturer details

EUDAMED SRN
FR-MF-000027377

Other devices from Promise proteomics

Properties & raw data

Show properties, registry sources and raw records
  • Human Tissues
  • Animal Tissues
  • Reagent
  • Professional Testing
  • New Device
Other properties (6)
  • Sterile: No
  • Microbial Substances: No
  • Self Testing: No
  • Near-Patient Testing: No
  • Companion Diagnostics: No
  • Surgical Instrument: No

Sources (1)

  • EUDAMED 284a44c6-ebd9-4fda-8d9a-1e2a08b70970 61 fields · synced 23 Oct 2026